ClinicalTrials.gg

Program

eratrectinib

Also written as “VC004 Capsules”, “VC004 low dose” and “VC004 high dose”.

Its studies are mostly in Neoplasm Metastasis, led by Jiangsu vcare pharmaceutical technology.

Furthest: phase 3, since Oct 24, 20246 company-led studies, 2 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu vcare pharmaceutical technology62 open or runningphase 3since Oct 24, 2024Oct 12, 2020Dec 30, 2026phase 3 · NCT06658353

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 12, 2020First study: phase 2 study in Neoplasm MetastasisFirst studyNCT04614740 · 115 enrolled · China
  2. Sep 1, 2022Phase 1 study in Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionNCT05528120 · 16 enrolled · China
  3. Jul 26, 2024Phase 1 study in Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionNCT06529445 · 84 enrolled · China
  4. Sep 28, 2024Phase 1 study in Neoplasm MetastasisNCT06619951 · 56 enrolled · China
  5. Oct 24, 2024Phase 3 study in Locally Advanced Solid TumorNCT06658353 · 54 planned · China
  6. Jul 23, 2026Phase 1 study in Pain in Bone MetastasesNCT07731685 · 26 planned · China

Ahead

  1. Dec 30, 2026Primary completion: phase 3 study in Locally Advanced Solid TumorNCT06658353
  2. Dec 30, 2027Primary completion: phase 1 study in Pain in Bone MetastasesNCT07731685

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07731685Pain in Bone Metastases · China1Not yet recruitingDec 30, 202726
NCT06658353Locally Advanced Solid Tumor · China3RecruitingDec 30, 202654
NCT06619951Neoplasm Metastasis · China1CompletedOct 31, 202456
NCT06529445Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion · China1CompletedAug 26, 202484
NCT05528120Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion · China1CompletedOct 28, 202216
NCT04614740Neoplasm Metastasis · China2UNKNOWNJan 31, 2024115

How it is read

Names in the registry

  • “VC004 Capsules”, 3 entries
  • “VC004 low dose”, 1 entry
  • “VC004 high dose”, 1 entry
  • “VC004 and Itraconazole”, 1 entry
  • “VC004 and rifampicin”, 1 entry

Codes read as this program: VC004.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.